Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Publikováno v:
Value in Health. 20:1279-1287
Objectives To assess the cost-effectiveness of basal insulin regimens for adults with type 1 diabetes mellitus in England. Methods A cost-utility analysis was conducted in accordance with the National Institute for Health and Care Excellence referenc
Publikováno v:
Value in Health. 20:1329-1335
Objectives To forecast lifetime outcomes and cost of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis (CF) with homozygous phe508del mutation from the US payer perspective. Methods A lifetime Markov model was developed from a
Autor:
SI Lopes, Philip Christopher McEwan, R. Urbaityte, Yogesh Punekar, Thomas Ward, AA Martin, Oliver Darlington
Publikováno v:
Value in Health. 21:S231-S232
Publikováno v:
Value in Health. 21:S76-S77
This study aimed to analyze (1) the cost-effectiveness of olanzapine orally disintegrating tablet (ODT) compared to olanzapine standard oral tablet (SOT) and (2) the cost-effectiveness of olanzapine-SOT compared to aripiprazole-SOT for patients with
Publikováno v:
Value in Health. 21:S216-S217
Publikováno v:
Value in Health. 20:A652-A653
Publikováno v:
Value in Health. 21:S129
Autor:
M. Bonnemaire, F. Bonnet, M.J. Cambron-Mellot, S. Gupta, J. Wu, Javier Escalada, Dirk Müller-Wieland, C. Nicholls
Publikováno v:
Value in Health. 21:S120
Publikováno v:
Value in Health. 21:S65
Publikováno v:
Value in Health. 18(7)
Overall survival (OS) and other important clinical trial end-points seem increasingly more elusive in supporting rapid and efficient incorporation of innovative cancer drugs in clinical practice. This study proposes a clinical trial based pharmacoeco